Polyoxometalates:metallodrug agents for combating amyloid aggregation

扫码查看

原文链接

NETL
NSTL
万方数据

外文摘要：Alzheimer's disease(AD)is a devastating neurodegenerative disease that affects～50 million people globally.The accumulation of amyloid-β(Aβ)plaques,a predominant pathological feature of AD,plays a crucial role in AD pathogenesis.In this respect,Aβ has been regarded as a highly promising therapeutic target for AD treatment.Polyoxometalates(POMs)are a novel class of metallodrugs being developed as modulators of Aβ aggregation,owing to their negative charge,polarity,and three-dimensional structure.Unlike traditional discrete inorganic complexes,POMs contain tens to hundreds of metal atoms,showcasing remarkable tunability and diversity in nuclearities,sizes,and shapes.The easily adjustable and structurally variable nature of POMs allows for their favorable interactions with Aβ.This mini-review presents a balanced overview of recent progress in using POMs to mitigate amyloidosis.Clear correlations between anti-amyloid activities and structural features of POMs are also elaborated in detail.Finally,we discuss the current challenges and future prospects of POMs in combating AD.

外文关键词：

amyloid inhibitionmetallodrugpolyoxometalateamyloid-βAlzheimer's disease

作者：

Mengmeng Ma、Zhenqi Liu、Huisi Zhao、Haochen Zhang、Jinsong Ren、Xiaogang Qu

展开 >

作者单位：

Laboratory of Chemical Biology and State Key Laboratory of Rare Earth Resource Utilization,Changchun Institute of Applied Chemistry,Chinese Academy of Sciences,Changchun 130022,China

School of Applied Chemistry and Engineering,University of Science and Technology of China,Hefei 230026,China

基金：

National Key R&D Program of ChinaNational Key R&D Program of ChinaNational Key R&D Program of ChinaNational Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaJilin Innovation Project

项目编号：

2019YFA07092022021YFF12007002022YFA120580421820102009222370062023DJ02

出版年：

2024

DOI：

10.1093/nsr/nwae226

国家科学评论(英文版)

CSTPCD

ISSN：

年,卷(期)：2024.11(7)

参考文献量1